A Phase 1 Study of ABBV-400 in People With Advanced Solid Tumors


Full Title

Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications


Researchers want to find the best dose of ABBV-400 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing or came back after treatment.

ABBV-400 targets cells that make too much of a protein called c-MET, which plays a role in cancer cell growth. By destroying these cells, ABBV-400 may help slow or stop the growth of cancer. ABBV-400 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a solid tumor that keeps growing or came back even after treatment.
  • Have completed prior cancer treatment at least 4 weeks before getting ABBV-400.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. James Harding’s office at 646-888-4314.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID